Consider this Bear Case Scenario for Abbott Laboratories (NYSE:ABT). An uphill battle in the diagnostics space where ABT must go toe to toe with market leader Roche, along with upstarts like Qiagen and Hologic. Medical therapy and coronary bypass have gained favor. This is not good for percutaneous coronary procedures.
George Gutowski writes from a caveat emptor perspective.